Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL303815 | 1.00 | KDM4E (0.44) | KDM4EL3MBTL1TDP1MAPTMAPK1 | |
| SCHEMBL14528163 | 0.78 | BACE1 (0.34) | KDM4EL3MBTL1TDP1MAPTMAPK1 | |
| SCHEMBL2262027 | 0.77 | BACE1 (0.50) | KDM4ETDP1MAPTPDPK1BACE1 | |
| SCHEMBL29367545 | 0.77 | BACE1 (0.50) | KDM4ETDP1MAPTPDPK1BACE1 | |
| SCHEMBL901849 | 0.77 | ALDH1A1 (0.42) | KDM4EL3MBTL1TDP1MAPTMAPK1 | |
| SCHEMBL29751038 | 0.77 | ALDH1A1 (0.42) | KDM4EL3MBTL1TDP1MAPTMAPK1 | |
| SCHEMBL30133425 | 0.77 | ALDH1A1 (0.42) | KDM4EL3MBTL1TDP1MAPTMAPK1 | |
| SCHEMBL1520112 | 0.77 | BACE1 (0.47) | KDM4EMAPTPDPK1BACE1HPGD | |
| SCHEMBL30005359 | 0.77 | BACE1 (0.47) | KDM4EMAPTPDPK1BACE1HPGD | |
| SCHEMBL31165772 | 0.74 | CYP1A2 (0.45) | KDM4EL3MBTL1TDP1MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4713330-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED Limited (CN) | 2026-03-25 | — | — | EP | disclosed |
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2025-10-14 | — | — | US | disclosed |
| WO-2024235286-A1 | TRICYCLIC COMPOUNDS AND USES THEREOF | HUTCHMED LIMITED (CN) | 2024-11-21 | — | — | WO | disclosed |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2024-02-15 | — | — | US | disclosed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. | 2022-12-15 | — | — | US | disclosed |
| EP-4087573-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250381187-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KDM4E 4105/4885L3MBTL1 3825/4885TDP1 3096/4885 |
| US-12440491-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KDM4E 4105/4885L3MBTL1 3825/4885TDP1 3096/4885 |
| US-20220395504-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KDM4E 4105/4885L3MBTL1 3825/4885TDP1 3096/4885 |
| US-20240050430-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | KDM4E 4105/4885L3MBTL1 3825/4885TDP1 3096/4885 |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | KDM4E 4105/4885L3MBTL1 3825/4885TDP1 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.